All In Biotech

NDA 017381 · King Pharms LLC

Silvadene

Silver Sulfadiazine · Topical · Sulfonamide Antibacterial

Priority review

Last checked: Nov 19, 2026Latest source record: Aug 1, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1973

Nov 26, 1973

Approved uses

1

Original approval plus efficacy supplements

Registered trials

51

7 Phase 3, 3 recruiting

FAERS reports

2,294

1,488 serious, 290 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 26, 2026.

INDICATIONS AND USAGE SILVADENE Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 26, 1973 Original approval · Type 2 - New Active Ingredient · priority review
1 products under this application
  • SILVADENE · SILVER SULFADIAZINE 1% · CREAM, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Silver Sulfadiazine" as an intervention, any sponsor and status, largest first.

All 51 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use161
  • pain152
  • fatigue150
  • product use in unapproved indication146
  • nausea136
  • death121
  • diarrhoea118
  • drug ineffective115
  • chronic kidney disease109
  • dyspnoea108
  • rash99
  • anxiety95

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200420
200517
200616
200726
200817
200942
201035
201134
201278
201349
201467
201598
2016200
2017151
2018181
2019185
2020194
2021204
2022176
2023160
2024119
2025112
2026112

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Silvadene (Silver Sulfadiazine)

2024 spending

$29K

Beneficiaries

867

1,023 claims

Per beneficiary

$33

$0.15 per unit

View as table
YearSpending
2020$48,462
2021$36,699
2022$29,338
2023$31,181
2024$28,883

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 196 on PubMed

Sponsor: King Pharms LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.